LOCKHEED MARTIN CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LOCKHEED MARTIN CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $75.05B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $71.04B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $67.57B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $65.98B | Jan 28, 2025 |
| FY2023 | Dec 31, 2021 | $67.04B | Jan 23, 2024 |
| FY2020 | Dec 31, 2020 | $17.03B | Jan 28, 2021 |
| FY2020 | Sep 27, 2020 | $16.50B | Jan 28, 2021 |
| FY2020 | Jun 28, 2020 | $16.22B | Jan 28, 2021 |
| FY2020 | Mar 29, 2020 | $15.65B | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | $15.88B | Jan 28, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $59.81B | Feb 7, 2020 |
| FY2019 | Dec 31, 2018 | $53.76B | Feb 7, 2020 |
| FY2019 | Dec 31, 2017 | $49.96B | Feb 7, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $15.14B | Feb 16, 2018 |
| FY2017 | Sep 24, 2017 | $12.17B | Feb 16, 2018 |
| FY2017 | Jun 25, 2017 | $12.69B | Feb 16, 2018 |
| FY2017 | Mar 26, 2017 | $11.06B | Feb 16, 2018 |
| FY2017 | Dec 31, 2016 | $13.75B | Feb 16, 2018 |
| FY2017 | Sep 25, 2016 | $11.55B | Feb 16, 2018 |
| FY2017 | Jun 26, 2016 | $11.58B | Feb 16, 2018 |
| FY2017 | Mar 27, 2016 | $10.37B | Feb 16, 2018 |
| FY2016 | Dec 31, 2015 | $11.52B | Feb 9, 2017 |
| FY2016 | Sep 27, 2015 | $10.06B | Feb 9, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.62B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $6.93B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $8.48B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $8.29B | Jan 28, 2025 |
| FY2023 | Dec 31, 2021 | $9.06B | Jan 23, 2024 |
| FY2022 | Dec 31, 2020 | $8.65B | Jan 26, 2023 |
| FY2021 | Dec 31, 2019 | $8.37B | Jan 25, 2022 |
| FY2020 | Dec 31, 2018 | $7.27B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $6.37B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $5.40B | Feb 8, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.02B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $5.34B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $6.92B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $5.73B | Jan 28, 2025 |
| FY2023 | Dec 31, 2021 | $6.32B | Jan 23, 2024 |
| FY2020 | Dec 31, 2020 | $1.79B | Jan 28, 2021 |
| FY2020 | Sep 27, 2020 | $1.70B | Jan 28, 2021 |
| FY2020 | Jun 28, 2020 | $1.63B | Jan 28, 2021 |
| FY2020 | Mar 29, 2020 | $1.72B | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | $1.50B | Jan 28, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.73B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $7.01B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $8.51B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $8.35B | Jan 28, 2025 |
| FY2023 | Dec 31, 2021 | $9.12B | Jan 23, 2024 |
| FY2020 | Dec 31, 2020 | $2.29B | Jan 28, 2021 |
| FY2020 | Sep 27, 2020 | $2.15B | Jan 28, 2021 |
| FY2020 | Jun 28, 2020 | $2.09B | Jan 28, 2021 |
| FY2020 | Mar 29, 2020 | $2.12B | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | $2.15B | Jan 28, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.00B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $1.60B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $1.50B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $1.70B | Jan 28, 2025 |
| FY2023 | Dec 31, 2021 | $1.50B | Jan 23, 2024 |
| FY2022 | Dec 31, 2020 | $1.30B | Jan 26, 2023 |
| FY2021 | Dec 31, 2019 | $1.30B | Jan 25, 2022 |
| FY2020 | Dec 31, 2018 | $1.30B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $1.20B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $988.00M | Feb 8, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.56B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $6.97B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $7.92B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $7.80B | Jan 28, 2025 |
| FY2023 | Dec 31, 2021 | $9.22B | Jan 23, 2024 |
| FY2022 | Dec 31, 2020 | $8.18B | Jan 26, 2023 |
| FY2021 | Dec 31, 2019 | $7.31B | Jan 25, 2022 |
| FY2020 | Dec 31, 2018 | $3.14B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $6.48B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $5.19B | Feb 8, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $942.00M | Feb 28, 2013 |
| FY2011 | Dec 31, 2011 | $814.00M | Feb 23, 2012 |
| FY2010 | Dec 31, 2010 | $820.00M | Feb 25, 2011 |
| FY2009 | Dec 31, 2009 | $852.00M | Feb 25, 2010 |
| FY2009 | Dec 31, 2008 | $926.00M | Feb 25, 2010 |
| FY2009 | Dec 31, 2007 | $940.00M | Feb 25, 2010 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.84B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $55.62B | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | $52.46B | Jan 28, 2025 |
| FY2023 | Dec 31, 2022 | $52.88B | Jan 23, 2024 |
| FY2022 | Dec 31, 2021 | $50.87B | Jan 26, 2023 |
| FY2021 | Dec 31, 2020 | $50.71B | Jan 25, 2022 |
| FY2020 | Dec 31, 2019 | $47.53B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $44.88B | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $46.62B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $47.81B | Feb 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.12B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $49.28B | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | $45.62B | Jan 28, 2025 |
| FY2023 | Dec 31, 2022 | $43.61B | Jan 23, 2024 |
| FY2022 | Dec 31, 2021 | $39.91B | Jan 26, 2023 |
| FY2021 | Dec 31, 2020 | $44.67B | Jan 25, 2022 |
| FY2020 | Dec 31, 2019 | $44.36B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $43.43B | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $47.40B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $46.20B | Feb 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.72B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $6.33B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $6.84B | Jan 29, 2026 |
| FY2025 | Dec 31, 2022 | $9.27B | Jan 29, 2026 |
| FY2024 | Dec 31, 2021 | $10.96B | Jan 28, 2025 |
| FY2021 | Dec 31, 2020 | $6.02B | Jan 25, 2022 |
| FY2020 | Dec 31, 2019 | $3.13B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $1.39B | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | ($850.00M) | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $1.51B | Feb 16, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.31B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $11.07B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $10.80B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $10.78B | Jan 28, 2025 |
| FY2023 | Dec 31, 2021 | $10.81B | Jan 23, 2024 |
| FY2022 | Dec 31, 2020 | $10.81B | Jan 26, 2023 |
| FY2021 | Dec 31, 2019 | $10.60B | Jan 25, 2022 |
| FY2020 | Dec 31, 2018 | $10.77B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $10.81B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $10.76B | Feb 8, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.03B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $14.55B | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | $15.40B | Jan 28, 2025 |
| FY2023 | Dec 31, 2022 | $16.94B | Jan 23, 2024 |
| FY2022 | Dec 31, 2021 | $21.60B | Jan 26, 2023 |
| FY2021 | Dec 31, 2020 | $21.64B | Jan 25, 2022 |
| FY2020 | Dec 31, 2019 | $18.40B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $15.43B | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $11.41B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $13.32B | Feb 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.12B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $2.48B | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | $1.44B | Jan 28, 2025 |
| FY2023 | Dec 31, 2022 | $2.55B | Jan 23, 2024 |
| FY2022 | Dec 31, 2021 | $3.60B | Jan 26, 2023 |
| FY2021 | Dec 31, 2020 | $3.16B | Jan 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.51B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $772.00M | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $2.86B | Feb 8, 2019 |
| FY2018 | Dec 31, 2016 | $1.84B | Feb 8, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.70B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $20.27B | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | $17.46B | Jan 28, 2025 |
| FY2023 | Dec 31, 2022 | $15.55B | Jan 23, 2024 |
| FY2022 | Dec 31, 2021 | $11.68B | Jan 26, 2023 |
| FY2021 | Dec 31, 2020 | $12.17B | Jan 25, 2022 |
| FY2020 | Dec 31, 2019 | $12.65B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $14.10B | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $14.26B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $14.28B | Feb 16, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 21 | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | 22 | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | 27 | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | 21 | Jan 28, 2025 |
| FY2023 | Dec 31, 2021 | 22 | Jan 23, 2024 |
| FY2020 | Dec 31, 2020 | 6 | Jan 28, 2021 |
| FY2020 | Sep 27, 2020 | 6 | Jan 28, 2021 |
| FY2020 | Jun 28, 2020 | 5 | Jan 28, 2021 |
| FY2020 | Mar 29, 2020 | 6 | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | 5 | Jan 28, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 21 | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | 22 | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | 27 | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | 21 | Jan 28, 2025 |
| FY2023 | Dec 31, 2021 | 22 | Jan 23, 2024 |
| FY2020 | Dec 31, 2020 | 6 | Jan 28, 2021 |
| FY2020 | Sep 27, 2020 | 6 | Jan 28, 2021 |
| FY2020 | Jun 28, 2020 | 5 | Jan 28, 2021 |
| FY2020 | Mar 29, 2020 | 6 | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | 5 | Jan 28, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 229.00M | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | 234.00M | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | 240.00M | Jan 28, 2025 |
| FY2023 | Dec 31, 2022 | 254.00M | Jan 23, 2024 |
| FY2021 | Dec 31, 2021 | 271.00M | Jan 25, 2022 |
| FY2020 | Dec 31, 2020 | 279.00M | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | 280.00M | Jan 28, 2021 |
| FY2017 | Dec 31, 2017 | 284.00M | Feb 16, 2018 |
| FY2017 | Dec 31, 2016 | 289.00M | Feb 16, 2018 |
| FY2016 | Dec 31, 2015 | 303.00M | Feb 9, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.13B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $3.06B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $3.06B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $3.02B | Jan 28, 2025 |
| FY2023 | Dec 31, 2021 | $2.94B | Jan 23, 2024 |
| FY2022 | Dec 31, 2020 | $2.76B | Jan 26, 2023 |
| FY2021 | Dec 31, 2019 | $2.56B | Jan 25, 2022 |
| FY2020 | Dec 31, 2018 | $2.35B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $2.16B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $2.05B | Feb 8, 2019 |